Bristol-Myers cancer immunotherapy advances on two fronts
July 20, 2015 at 13:44 PM EDT
July 20 (Reuters) - Bristol-Myers Squibb Co's Opdivo, a new oncology drug that makes cancer cells more susceptible to the immune system, on Monday won European approval to treat a form of lung cancer and was also found to be beneficial in patients with advanced kidney cancer.